WallStSmart

Accuray Incorporated (ARAY)vsStryker Corporation (SYK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Stryker Corporation generates 5929% more annual revenue ($25.84B vs $428.57M). SYK leads profitability with a 14.4% profit margin vs -10.8%. SYK appears more attractively valued with a PEG of 1.55. SYK earns a higher WallStSmart Score of 63/100 (C+).

ARAY

Hold

37

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 4.0Quality: 3.5
Piotroski: 5/9Altman Z: -0.03

SYK

Buy

63

out of 100

Grade: C+

Growth: 8.0Profit: 8.0Value: 3.3Quality: 6.5
Piotroski: 3/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ARAY.

SYKSignificantly Overvalued (-51.9%)

Margin of Safety

-51.9%

Fair Value

$229.20

Current Price

$348.15

$118.95 premium

UndervaluedFair: $229.20Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ARAY1 strengths · Avg: 10.0/10
Price/BookValuation
0.8x10/10

Reasonable price relative to book value

SYK4 strengths · Avg: 8.3/10
Market CapQuality
$128.87B9/10

Large-cap with strong market position

Operating MarginProfitability
27.0%8/10

Strong operational efficiency at 27.0%

EPS GrowthGrowth
44.1%8/10

Earnings expanding 44.1% YoY

Free Cash FlowQuality
$1.06B8/10

Generating 1.1B in free cash flow

Areas to Watch

ARAY4 concerns · Avg: 2.3/10
Market CapQuality
$37.17M3/10

Smaller company, higher risk/reward

PEG RatioValuation
29.492/10

Expensive relative to growth rate

Return on EquityProfitability
-110.6%2/10

ROE of -110.6% — below average capital efficiency

Revenue GrowthGrowth
-7.4%2/10

Revenue declined 7.4%

SYK3 concerns · Avg: 3.7/10
PEG RatioValuation
1.554/10

Expensive relative to growth rate

P/E RatioValuation
35.3x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ARAY

The strongest argument for ARAY centers on Price/Book.

Bull Case : SYK

The strongest argument for SYK centers on Market Cap, Operating Margin, EPS Growth.

Bear Case : ARAY

The primary concerns for ARAY are Market Cap, PEG Ratio, Return on Equity. Debt-to-equity of 4.37 is elevated, increasing financial risk.

Bear Case : SYK

The primary concerns for SYK are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

ARAY profiles as a turnaround stock while SYK is a value play — different risk/reward profiles.

ARAY carries more volatility with a beta of 1.39 — expect wider price swings.

SYK is growing revenue faster at 9.4% — sustainability is the question.

SYK generates stronger free cash flow (1.1B), providing more financial flexibility.

Bottom Line

SYK scores higher overall (63/100 vs 37/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Accuray Incorporated

HEALTHCARE · MEDICAL DEVICES · USA

Accuray Incorporated designs, develops and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa and the rest of the Asia Pacific region. The company is headquartered in Sunnyvale, California.

Visit Website →

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Want to dig deeper into these stocks?